Want to see AU:BIT full AI Analyst Report?
Top Page
Biotron
(Sydney:BIT)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▲(450.00% Upside)
Action:Reiterated
Date:08/30/26
The score is primarily weighed down by weak financial performance—persistent losses, ongoing cash burn, and revenue collapsing to zero in 2026—suggesting continued reliance on external funding. A relatively low-debt balance sheet provides some risk mitigation, but valuation metrics are not supportive (negative P/E) and technical signals are unavailable, keeping the overall score near the low end.
Positive Factors
Low Leverage
Very low debt reduces interest and refinancing pressure, preserving financial flexibility while the company funds antiviral development. This provides some protection against solvency stress, although it does not offset the need to improve earnings and cash generation.
Negative Factors
Persistent Losses
Recurring net losses indicate that the business has not established a sustainable earnings model. Continued deficits can constrain research investment, weaken equity over time, and increase dependence on external capital until products generate meaningful revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt reduces interest and refinancing pressure, preserving financial flexibility while the company funds antiviral development. This provides some protection against solvency stress, although it does not offset the need to improve earnings and cash generation.
Read all positive factors
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.57M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth-100.00%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,785,205,000
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.13
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotron Business Overview & Revenue Model
Company Description
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase...
How the Company Makes Money
null...
Biotron Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -868.00 | 0.00 | 1.81M | 1.65M | 1.43M | 1.56M |
| Gross Profit | -1.65K | -1.91K | 1.81M | 1.65M | 1.39M | 1.51M |
| EBITDA | -1.92M | -1.93M | -333.81K | -5.04M | -4.88M | -2.73M |
| Net Income | -1.94M | -1.52M | -318.57K | -3.44M | -3.49M | -2.78M |
Balance Sheet | ||||||
| Total Assets | 3.86M | 3.74M | 980.40K | 493.48K | 4.14M | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 1.55M | 931.68K | 393.20K | 3.98M | 1.74M |
| Total Debt | 0.00 | 0.00 | 0.00 | 7.13K | 45.27K | 77.24K |
| Total Liabilities | 1.16M | 817.93K | 428.51K | 737.51K | 962.49K | 813.57K |
| Stockholders Equity | 2.70M | 2.92M | 551.89K | -244.03K | 3.17M | 1.09M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -1.78M | -568.87K | -3.57M | -3.29M | -2.44M |
| Operating Cash Flow | -1.92M | -1.78M | -565.80K | -3.57M | -3.29M | -2.44M |
| Investing Cash Flow | 111.51K | 111.51K | -3.07K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.58M | 2.29M | 1.11M | -22.62K | 5.53M | -33.17K |
Biotron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$80.94M | 22.98 | 46.74% | ― | 29.68% | 1520.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$16.47M | -3.41 | -31.88% | ― | 5.85% | 42.92% | |
43 Neutral | AU$5.57M | -5.34 | -54.03% | ― | ― | -100.00% | |
43 Neutral | AU$353.02M | -43.27 | -42.35% | ― | 145.32% | 25.75% | |
43 Neutral | AU$107.02M | -6.27 | 84.67% | ― | ― | 42.51% | |
41 Neutral | AU$7.45M | -2.27 | -143.11% | ― | ― | 38.52% |
* Healthcare Sector Average
AU:BIT
Biotron
―
―
―
AU:SPL
Starpharma Holdings Limited
0.75
0.62
515.70%
AU:IMC
Immuron Limited
0.04
-0.03
-39.73%
AU:BGT
Bio-Gene Technology Ltd.
0.02
>-0.01
-26.09%
AU:BIO
Biome Australia Ltd
0.37
-0.09
-19.57%
AU:RCE
Recce Pharmaceuticals Ltd.
0.32
-0.09
-20.99%
Biotron Corporate Events
Biotron Files Updated ASX Corporate Governance Appendix 4G for FY 2026
Aug 27, 2026
Biotron Limited has lodged its Appendix 4G and updated corporate governance statement for the year ended 30 June 2026, confirming that the statement is available on its website and has been approved by the board as at 27 August 2026. The filing ou...
Biotron Outlines Governance and Diversity Framework for FY2026
Aug 27, 2026
Biotron has detailed its corporate governance framework for the year to 30 June 2026, confirming broad alignment with the ASX Corporate Governance Principles and Recommendations. The board retains responsibility for strategy, financial oversight, ...
Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty
Aug 27, 2026
Biotron Limited, an ASX-listed Australian biotechnology company, focuses on antiviral drug development for infectious diseases with a research-led approach. Its activities are concentrated in the life sciences sector, where clinical milestones and...
Biotron Advances Hepatitis B Candidate BIT-HBV001 Toward Human Trials After Strong Preclinical Data
Aug 17, 2026
Biotron has reported new preclinical data from The Scripps Research Institute showing that its lead candidate BIT-HBV001 exhibits strong antiviral activity against both Hepatitis B Virus and Hepatitis Delta Virus in cell-based studies. The compoun...
Biotron Updates Market on Directors’ Shareholding Changes
Jul 15, 2026
Biotron Limited has notified the ASX of changes in the shareholdings of directors Paul Kasian and Graeme Wald, in accordance with listing rule 3.19A. The disclosure reinforces the company’s commitment to regulatory compliance and transparent...
Biotron Seeks ASX Quotation for 83 Million New Shares
Jul 13, 2026
Biotron Limited has applied for quotation on the ASX of 83,333,333 new ordinary fully paid shares, expanding its listed securities base under the ticker BIT. The newly issued shares, dated 13 July 2026, arise from the exercise or conversion of exi...
Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway
Jul 13, 2026
Biotron has met the first milestone under its Sedarex acquisition after securing formal feedback from the European Medicines Agency on the regulatory pathway for SedRx. The EMA guidance gives the company a clearer roadmap for designing pivotal cli...
Biotron Lists Additional Ordinary Shares Following Option Conversions
Jun 17, 2026
Biotron Limited has applied for quotation on the ASX of 5,720 new ordinary fully paid shares, to be listed under its existing ticker BIT. The securities arise from the exercise or conversion of existing options or other convertible instruments, re...
Biotron Secures R&D Tax Rebate to Support Antiviral Drug Development
Jun 3, 2026
Biotron Limited has received an RD Tax Incentive rebate of $525,869 from the Australian Government for the 2024/25 financial year, reflecting 43.5% of its eligible research and development expenditure. The rebate, derived from its antiviral drug d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.